Lido Advisors LLC lessened its holdings in Medifast Inc (NYSE:MED - Free Report) by 44.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 183,035 shares of the specialty retailer's stock after selling 147,668 shares during the period. Lido Advisors LLC owned about 1.65% of Medifast worth $1,865,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer's stock valued at $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Medifast in the third quarter valued at about $37,000. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Medifast during the 4th quarter valued at about $47,000. State of Wyoming acquired a new position in Medifast during the 4th quarter worth approximately $59,000. Finally, Strs Ohio acquired a new position in Medifast during the 1st quarter worth approximately $78,000. Institutional investors and hedge funds own 95.51% of the company's stock.
Analyst Ratings Changes
Several analysts have issued reports on the stock. Zacks Research raised shares of Medifast from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 13th. Weiss Ratings downgraded shares of Medifast from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Medifast presently has an average rating of "Hold" and an average target price of $12.00.
Check Out Our Latest Report on MED
Medifast Trading Down 0.3%
Medifast stock opened at $9.65 on Monday. Medifast Inc has a 52 week low of $9.22 and a 52 week high of $15.20. The stock has a market cap of $107.30 million, a P/E ratio of -5.27 and a beta of 0.65. The stock has a 50 day moving average of $11.38 and a 200-day moving average of $11.10.
Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.36. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. The business had revenue of $76.04 million during the quarter, compared to analyst estimates of $69.20 million. Medifast has set its FY 2026 guidance at -2.750--1.550 EPS and its Q2 2026 guidance at -1.000--0.500 EPS. As a group, equities analysts predict that Medifast Inc will post -1.97 earnings per share for the current fiscal year.
Insider Activity at Medifast
In other news, Director Scott Schlackman purchased 2,500 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the purchase, the director owned 30,549 shares of the company's stock, valued at approximately $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.70% of the company's stock.
Medifast Profile
(
Free Report)
Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
